MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting

OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases will
present results of viral resistance studies with its anti-HCV agent celgosivir
at the 14th International Symposium on Hepatitis C Virus and Related Viruses
(www.hcv2007.com) being held September 9th to 13th 2007 in Glasgow, Scotland.
    The presentation entitled: "Celgosivir (MX-3253) Resistance Profile Using
Bovine Viral Diarrhea Virus" will be made today from 5:30pm to 8:00pm, Glasgow
time (9:30am - noon Pacific Time) by Dominique Dugourd, Ph.D., Microbiology
Group Leader at MIGENIX. A copy of the presentation and the related Abstract
(abstract P-223) will be available at www.migenix.com at the start of the
presentation. The conference covers a broad spectrum of topics from molecular
virology to new antiviral therapies and attracts major scientists and thought
leaders in the field.
    Jacob Clement, Ph.D., CSO at MIGENIX and coauthor of the paper, believes
that the results of these laboratory studies with the accepted HCV surrogate
virus BVDV, indicate that the emergence of resistance in a clinical setting is
unlikely to occur. "We were unable to induce viral resistance to celgosivir
even after repeated exposure to high levels of the agent in a system which
rapidly develops relatively high levels of resistance to other direct acting

    About Celgosivir (MX-3253)

    Celgosivir is an oral alpha-glucosidase I inhibitor and is currently the
only anti-HCV drug in clinical development that acts on host-directed
glycosylation. In preclinical studies, celgosivir has shown excellent in vitro
synergy with various interferons in the clinic or in development including
Pegasys, PEG-Intron, Infergen, Alferon and IFN-omega (with or without
ribavirin) and other drugs in development for the treatment of HCV (e.g.
polymerase inhibitors) and therefore has the potential to be included as part
of multiple combination approaches to improve efficacy in anti-HCV therapy.

    About MIGENIX

    MIGENIX is committed to advancing therapy, improving health, and
enriching life by developing and commercializing drugs primarily in the area
of infectious diseases. The Company's clinical programs include drug
candidates for the treatment of chronic hepatitis C infections (Phase II and
preclinical), the prevention of catheter-related infections (Phase III) and
the treatment of dermatological diseases (Phase II). MIGENIX is headquartered
in Vancouver, British Columbia, Canada with US operations in San Diego,
California. Additional information can be found at www.migenix.com.

    "Jim DeMesa"

    James M. DeMesa, M.D.
    President & CEO


    This news release contains forward-looking statements within the meaning
of the United States Private Securities Litigation Reform Act of 1995, and
forward-looking information within the meaning of applicable securities laws
in Canada, (collectively referred to as "forward-looking statements").
Statements, other than statements of historical fact, are forward-looking
statements. By their nature, forward-looking statements involve numerous
assumptions, known and unknown risks and uncertainties, both general and
specific, that contribute to the possibility that the predictions, forecasts,
projections and other things contemplated by the forward-looking statements
will not occur.
    Although our management believes that the expectations represented by
such forward-looking statements are reasonable, there is significant risk that
the forward-looking statements may not be achieved, and the underlying
assumptions thereto will not prove to be accurate. Forward-looking statements
in this news release include, but are not limited to, statements concerning
our scientist's expectations that the emergence of resistance to celgosivir in
a clinical setting is unlikely to occur
    With respect to the forward-looking statements contained in this news
release, we have made numerous assumptions regarding, among other things: the
predictiveness of the Bovine Viral Diarrhea Virus (BVDV) in vitro assay in
assessing the resistance profile of celgosivir.
    Actual results or events could differ materially from the plans,
intentions and expectations expressed or implied in any forward-looking
statements, including the underlying assumptions thereto, as a result of
numerous risks, uncertainties and other factors including: uncertainties
related to early stage of technology and product development; uncertainties as
to the requirement that a drug be found to be safe and effective after
extensive clinical trials and the possibility that the results of such trials,
if completed, will not establish the safety or efficacy of our products; and
other risks and uncertainties which may not be described herein. Certain of
these factors and other factors are described in detail in the Company's
Annual Information Form and Annual Report on Form 20-F for and other filings
with the Canadian securities regulatory authorities and the U.S. Securities &
Exchange Commission.
    Forward-looking statements are based on our current expectations and
MIGENIX assumes no obligations to update such information to reflect later
events or developments.

    The Toronto Stock Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this release.

For further information:

For further information: Art Ayres, MIGENIX Inc., Tel: (604) 221-9666
Ext. 233, aayres@migenix.com; Dian Griesel, Ph.D., Investor Relations Group,
Tel: (212) 825-3210, Theproteam@aol.com

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890